A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
Soria, J.C., Gan, H.K., Blagden, S.P., Plummer, R., Arkenau, H.T., Ranson, M., Evans, T.R.J., Zalcman, G., Bahleda, R., Hollebecque, A., Lemech, C., Dean, E., Brown, J., Gibson, D., Peddareddigari, V., Murray, S., Nebot, N., Mazumdar, J., Swartz, L., Auger, K.R., Fleming, R.A., Singh, R., Millward, M.
Published in Annals of oncology (01.12.2016)
Published in Annals of oncology (01.12.2016)
Get full text
Journal Article
610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma
Soria, J.C, Plummer, R, Ranson, M, Gan, H, Arkenau, H.T, Zalcman, G, Blagden, S, Evans, T.R.J, Peddareddigari, V, Mazumdar, J, Murray, S, Gibson, D, Fleming, R.A, Auger, K, Millward, M
Published in European journal of cancer (1990) (01.11.2012)
Published in European journal of cancer (1990) (01.11.2012)
Get full text
Journal Article
613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors
Gan, H, Nebot, N, Soria, J.C, Arkenau, H.T, Blagden, S, Plummer, R, Ranson, M, Evans, T.R.J, Zalcman, G, Peddareddigari, V, Gibson, D, Murray, S, Mazumdar, J, Fleming, R, Auger, K, Millward, M
Published in European journal of cancer (1990) (01.11.2012)
Published in European journal of cancer (1990) (01.11.2012)
Get full text
Journal Article
373 The oral MEK1/MEK2 inhibitor, GSK1120212, effectively inhibits the MAPK pathway: pharmacokinetic, pharmacodynamic, and clinical response relationship
Gordon, M.S, Infante, J.R, Messersmith, W, Fecher, L.A, Vogelzang, N.J, Cox, D, DeMarini, D.J, Xu, Y, Peddareddigari, V, Falchook, G
Published in European journal of cancer supplements (2010)
Published in European journal of cancer supplements (2010)
Get full text
Journal Article
890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL
Tholouli, E., Osborne, W., Bachier, C., Ramakrishnan, A., Marzolini, M., Irvine, D., McSweeney, P., Bartlet, N., Zhang, Y., Thomas, S., Al-Hajj, M., Pule, M., Jonnaert, M., Peddareddigari, V., Khokhar, N., Chen, R., Ardesha, K.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer
Messersmith, W. A., Falchook, G. S., Fecher, L. A., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., Peddareddigari, V. G., Xu, Y., Bendell, J. C., Infante, J. R.
Published in Journal of clinical oncology (01.02.2011)
Published in Journal of clinical oncology (01.02.2011)
Get full text
Journal Article
Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy
Peddareddigari, V. R., Miller, P. W., Nebiyou, B. B., Overwijk, W. W., Ross, M. I., Lee, J. E., Gershenwald, J. E., Prieto, V. G., Hwu, P., Radvanyi, L.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article